Skip to main content
NewAmsterdam Pharma Co N.V. logo

NewAmsterdam Pharma Co N.V. — Investor Relations & Filings

Ticker · NAMS ISIN · NL00150012K9 LEI · 984500B6549TF6E14D36 US Professional, scientific and technical activities
Filings indexed 373 across all filing types
Latest filing 2025-03-26 Regulatory Filings
Country NL Netherlands
Listing US NAMS

About NewAmsterdam Pharma Co N.V.

https://ir.newamsterdampharma.com/

NewAmsterdam Pharma Co N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases where currently approved treatments have not been sufficiently successful or well-tolerated. The company's lead product candidate is obicetrapib, an oral, low-dose, once-daily CETP inhibitor. It is being investigated as a therapy to lower low-density lipoprotein cholesterol (LDL-C) as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients. The company aims to address the unmet need for a potent, cost-effective, and convenient LDL-lowering treatment. In addition to its dyslipidemia program, the company also explores treatments for other metabolic disorders.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-03-26 English
4
Director's Dealing
2025-03-26 English
4
Director's Dealing
2025-03-19 English
Regulatory Filings 2025
Regulatory Filings
2025-03-11 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to an 'at the market' offering of ordinary shares up to $250 million. It includes detailed information about the offering, use of proceeds, risk factors, plan of distribution, and corporate information. The document is a registration and offering prospectus, which is a type of capital raising disclosure. It is not an annual report, earnings release, or other financial report. The key indicators are the mention of the Sales Agreement, the offering size, the plan of distribution, and the use of proceeds sections, all typical of a capital/financing update. Therefore, the document fits best under the category 'Capital/Financing Update' (CAP).
2025-03-10 English
Director's Dealing 2025
Director's Dealing
2025-03-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.